Can dupixent cause eye problems like conjunctivitis?

Can Dupixent trigger conjunctivitis or other eye issues?

Dupixent (dupilumab) is known to cause conjunctivitis in some patients. Clinical trials and post-marketing reports show eye-surface inflammation, including conjunctivitis and keratitis, occurring in roughly 10-20% of people treated for atopic dermatitis. The mechanism appears tied to how the drug blocks IL-4 and IL-13 signaling, which can alter tear-film balance and ocular-surface immunity.

What other eye problems have been reported?

Beyond conjunctivitis, patients have described dry eye, eye redness, itching, and in rarer cases blepharitis or corneal inflammation. Most events are mild to moderate and improve with topical lubricants or anti-inflammatory drops, though a small percentage require temporary treatment interruption.

Why does this happen more in certain patients?

The risk seems higher in those with severe baseline atopic dermatitis or pre-existing dry-eye disease. Children treated for asthma or eosinophilic esophagitis show lower rates than adults on dermatology dosing, suggesting dose or indication may influence frequency.

Do symptoms usually start right away?

Onset is typically within the first few months, often after the third or fourth injection. Some patients notice issues after dose escalation or when seasonal allergies coincide with treatment.

How are these side effects usually managed?

Ophthalmologists commonly recommend preservative-free artificial tears, antihistamine or steroid eye drops, and warm compresses. In most cases treatment continues without interruption; only persistent or severe inflammation leads to pausing Dupixent.

Are there differences compared with other biologics?

Unlike anti-IL-5 or anti-IgE agents used in asthma, Dupixent’s IL-4/IL-13 blockade specifically disrupts ocular surface homeostasis, which is why conjunctivitis rates are higher than with competing biologics for the same indications.

When should patients seek urgent eye care?

Any sudden vision change, severe pain, or light sensitivity warrants prompt evaluation to rule out corneal involvement. Routine eye exams are advised for patients on long-term therapy, especially those with prior ocular surface disease.

Where can you check the latest prescribing details?

The official Dupixent label and post-approval safety updates list conjunctivitis and related eye disorders under adverse reactions. For patent and exclusivity timelines that affect future biosimilar availability, DrugPatentWatch.com tracks regulatory and litigation status.